Laporan Unifi tentang kemajuan di tengah tantangan industri oleh Investing.com

about our outlook for the year. We are managing costs and preserving cash, with a focus on reducing variable expenses and reinvesting savings into innovation and margin expansion. We expect to see a gradual recovery in the first half of 2025, followed by a stronger resurgence in the second half.

In terms of our financial projections, we anticipate net sales for the first quarter of fiscal 2025 to be between $147 million and $153 million, representing a 10% growth year-over-year at the midpoint. Adjusted EBITDA for the first quarter is projected to be between $1 million and $3 million, showing a significant improvement from the previous year. Capital expenditures for fiscal 2025 are estimated to be between $10 million and $12 million.

Overall, we are optimistic about our future performance, with expectations of over 10% year-over-year top-line growth, positive EBITDA each quarter, and a significant increase in gross profit and margin. Our focus on diversifying our product offerings and expanding into new markets, combined with our commitment to sustainability and innovation, positions us well for success in the coming year.

Thank you for your continued support, and we look forward to updating you on our progress in the next earnings call. Now, I will turn it over to Eddie and A.J. for a more detailed review of our fourth quarter performance. Thank you.

MEMBACA  Mengapa Viking Therapeutics bisa menjadi sesuatu yang cukup menakjubkan